Taiwan Bio Therapeutics (ROCO:6892) Total Stockholders Equity : NT$1,020.6 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Taiwan Bio Therapeutics Total Stockholders Equity?

Taiwan Bio Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was NT$1,020.6 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Taiwan Bio Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 was NT$12.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Taiwan Bio Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.33.

Taiwan Bio Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Taiwan Bio Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Bio Therapeutics Total Stockholders Equity Chart

Taiwan Bio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

67.18

256.50

526.83

613.29

1,091.39

Taiwan Bio Therapeutics Quarterly Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial								-	886.00	774.44	1,091.39	1,020.61

Taiwan Bio Therapeutics (ROCO:6892) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Taiwan Bio Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1020.605	-	0)	/	84.482
	=	12.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Taiwan Bio Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(30.67	+	306.414)	/	1020.605
	=	0.33

Taiwan Bio Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Taiwan Bio Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiwan Bio Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Bio Therapeutics Inc (ROCO:6892) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744

Website

https://www.twbio-thera.com

Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.

Taiwan Bio Therapeutics Headlines

No Headlines